İLKNUR DELİKTAŞ ONUR, HATİCE GÜLGÜN FIRAT, ELİF SERTESEN, CENGİZ KARAÇİN, ÖZTÜRK ATEŞ
Annals of Clinical and Analytical Medicine - 2024;15(11):794-798
Aim: In recent years, neoadjuvant chemotherapy constitutes the basic building blocks of thetreatment scheme in the treatment of breast cancer. Randomized controlled studies in recent years have shown that neoadjuvant chemotherapy and dual anti-Her2(human epidermal growth factor receptor 2) combinations increase the pathological complete response and contribute to overall survival in Her2 positive breast cancer. The aim of this study is to compare the pathological complete response rates of patients receiving neoadjuvant chemotherapy-trastuzumab (CT) and patients receiving neoadjuvant chemotherapy-trastuzumab-pertuzumab (CTP) and present real-life data. Material and methods: 79 patients who received neoadjuvant CT and 155 patients who received CTP were included in the study. Pathological complete response rates of two independent groups were compared. Variables that predicted pathological complete response in both groups were examined. Results: In real life, we found that the pathological complete response rates in patients receiving neoadjuvant CTP were much higher than the rates in patients receiving neoadjuvant CT, even higher than the rates in randomized controlled studies that led to the introduction of dual blockade into the literature. Discussion: We think that neoadjuvant chemotherapy and dual anti-Her2 therapy are the optimal treatment for Her2 positive breast cancer.
